Want to see NL:DSFIR full AI Analyst Report?
Top Page
DSM-Firmenich AG
(DSFIR)
Select Model
Select Model
Rating:67Neutral
Price Target:
€118.00
▲(28.68% Upside)
Action:Reiterated
Date:08/02/26
The score is driven primarily by solid financial underpinnings (strong revenue rebound, improved gross margin, and positive free cash flow) but capped by ongoing net losses and negative ROE. Technicals add support due to a strong uptrend above key moving averages, while valuation is constrained by a negative P/E despite a moderate dividend yield.
Positive Factors
Revenue and Gross Margin Recovery
The combination of strong revenue recovery and higher gross margin indicates improving demand, pricing, product mix, or cost control. If sustained, this creates greater operating leverage and supports reinvestment in the company’s differentiated ingredient and formulation capabilities.
Negative Factors
Persistent Net Losses
Sustained net losses and negative returns on equity weaken confidence that the company is currently converting its asset and capital base into durable shareholder earnings. Continued losses could constrain internal investment capacity and make future profitability dependent on operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Margin Recovery
The combination of strong revenue recovery and higher gross margin indicates improving demand, pricing, product mix, or cost control. If sustained, this creates greater operating leverage and supports reinvestment in the company’s differentiated ingredient and formulation capabilities.
Read all positive factors
DSM-Firmenich AG (DSFIR) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€26.09B
Dividend Yield2.29%
Average Volume (3M)688.90K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth-44.75%
EPS Growth-301.20%
CountryNL
Employees28,550
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-4.82
Shares Outstanding253,626,950
10 Day Avg. Volume599,949
30 Day Avg. Volume688,899
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€91.67Price Target Upside-0.04% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)3.69
Revenue Forecast (FY)€9.28B
DSM-Firmenich AG Business Overview & Revenue Model
Company Description
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfu...
How the Company Makes Money
DSM-Firmenich makes money mainly by selling specialty ingredients and formulated solutions to business customers (B2B) under long-term supply relationships and project-based development work. Revenue is generated across several major streams: (1) ...
DSM-Firmenich AG Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
68
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.52B | 9.03B | 9.05B | 10.63B | 8.39B | 11.44B |
| Gross Profit | 3.99B | 3.53B | 3.55B | 2.61B | 2.69B | 4.19B |
| EBITDA | 2.07B | 1.61B | 1.60B | 1.31B | 1.38B | 1.50B |
| Net Income | -1.27B | -1.08B | 250.00M | 2.14B | 460.00M | 872.00M |
Balance Sheet | ||||||
| Total Assets | 30.45B | 29.34B | 33.75B | 34.27B | 17.40B | 16.02B |
| Cash, Cash Equivalents and Short-Term Investments | 2.31B | 1.90B | 2.72B | 2.56B | 2.88B | 2.05B |
| Total Debt | 6.76B | 5.66B | 5.28B | 4.83B | 3.06B | 3.10B |
| Total Liabilities | 12.47B | 10.92B | 11.05B | 11.20B | 6.56B | 6.62B |
| Stockholders Equity | 17.83B | 18.24B | 22.51B | 22.91B | 10.74B | 9.32B |
Cash Flow | ||||||
| Free Cash Flow | 764.50M | 624.00M | 1.01B | 710.00M | 279.00M | 994.00M |
| Operating Cash Flow | 1.82B | 1.39B | 1.78B | 1.26B | 923.00M | 1.43B |
| Investing Cash Flow | -1.26B | 392.00M | -252.00M | -726.00M | 871.00M | 208.00M |
| Financing Cash Flow | -884.50M | -2.58B | -1.33B | -820.00M | -598.00M | -984.00M |
DSM-Firmenich AG Technical Analysis
Positive
91.70
Price Trends
97.40
Positive
90.71
Positive
76.51
Positive
Market Momentum
3.69
Negative
69.66
Neutral
83.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:DSFIR, the sentiment is Positive. The current price of 91.7 is below the 20-day moving average (MA) of 103.39, below the 50-day MA of 97.40, and above the 200-day MA of 76.51, indicating a bullish trend. The MACD of 3.69 indicates Negative momentum. The RSI at 69.66 is Neutral, neither overbought nor oversold. The STOCH value of 83.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:DSFIR.
DSM-Firmenich AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €26.09B | -22.60 | ― | 2.29% | -44.75% | -301.20% | |
66 Neutral | €10.09B | 15.44 | 13.55% | 3.37% | -5.00% | 1020.46% | |
64 Neutral | €680.56M | 11.62 | 13.37% | 6.09% | -2.56% | -15.44% | |
62 Neutral | €5.96B | 25.90 | 11.06% | 1.79% | 2.64% | -14.83% | |
60 Neutral | €1.57B | 25.19 | 8.30% | 2.55% | -3.37% | -8.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
40 Underperform | €98.31M | -2.60 | -25.04% | ― | -32.85% | 26.72% |
* General Sector Average
NL:DSFIR
DSM-Firmenich AG
108.95
37.64
52.79%
NL:AKZA
Akzo Nobel NV
58.84
1.27
2.20%
NL:ACOMO
Acomo N.V.
23.00
0.45
1.97%
NL:AVTX
Avantium N.V.
3.90
-2.52
-39.20%
NL:CRBN
Corbion NV
27.20
11.03
68.24%
NL:IMCD
IMCD N.V.
101.00
10.03
11.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.